Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics is viewed favorably because interim ENDURE data showed no acute liver injury among 11 patients receiving prophylactic sirolimus, while untreated patients had ALI rates of 17% in ambulatory and 33% in non-ambulatory groups, supporting a practical risk-mitigation strategy for Elevidys. The company also strengthened the franchise’s clinical narrative with EMBARK Part 2 crossover data, where 60 treated patients showed slower PROMIS mobility decline versus 25 external controls and a higher probability of improvement, reinforcing the therapy’s functional benefit. Finally, the $39M settlement of the REGENX/UPenn patent dispute removes a key legal overhang, allowing investors to focus more on Sarepta’s commercial-stage rare-disease portfolio and upcoming 1Q:27 safety and expression data.

Sarepta Therapeutics is facing a fragile fundamental setup because ELEVIDYS’ randomized evidence remains inconclusive: neither Study 102 nor EMBARK showed statistically significant NSAA benefit, and the combined estimate still includes zero. The bullish external-control and pooled correlation data are weakened by post hoc design choices, missing follow-up, and unresolved safety concerns, including 715 commercially treated patients showing a 19% treatment-related ALI rate and 7% serious ALI-related hospitalization rates. With 2Q26 ELEVIDYS revenue at $98.1M, down 3.8% sequentially, and key safety data still pending in 1Q27, the company faces soft near-term commercialization and regulatory overhang across its DMD franchise.